Please use this identifier to cite or link to this item: http://hdl.handle.net/2445/106522
Full metadata record
DC FieldValueLanguage
dc.contributor.authorAntó i Boqué, Josep Maria-
dc.contributor.authorKogevinas, Manolis-
dc.contributor.authorSunyer Deu, Jordi-
dc.date.accessioned2017-02-06T08:37:41Z-
dc.date.available2017-02-06T08:37:41Z-
dc.date.issued2016-12-30-
dc.identifier.issn2045-7022-
dc.identifier.urihttp://hdl.handle.net/2445/106522-
dc.description.abstractThe Allergic Rhinitis and its Impact on Asthma (ARIA) initiative commenced during a World Health Organization workshop in 1999. The initial goals were (1) to propose a new allergic rhinitis classification, (2) to promote the concept of multi-morbidity in asthma and rhinitis and (3) to develop guidelines with all stakeholders that could be used globally for all countries and populations. ARIA—disseminated and implemented in over 70 countries globally—is now focusing on the implementation of emerging technologies for individualized and predictive medicine. MASK [MACVIA (Contre les Maladies Chroniques pour un Vieillissement Actif)-ARIA Sentinel NetworK] uses mobile technology to develop care pathways for the management of rhinitis and asthma by a multi-disciplinary group and by patients themselves. An app (Android and iOS) is available in 20 countries and 15 languages. It uses a visual analogue scale to assess symptom control and work productivity as well as a clinical decision support system. It is associated with an inter-operable tablet for physicians and other health care professionals. The scaling up strategy uses the recommendations of the European Innovation Partnership on Active and Healthy Ageing. The aim of the novel ARIA approach is to provide an active and healthy life to rhinitis sufferers, whatever their age, sex or socio-economic status, in order to reduce health and social inequalities incurred by the disease.-
dc.format.extent14 p.-
dc.format.mimetypeapplication/pdf-
dc.language.isoeng-
dc.publisherBioMed Central-
dc.relation.isformatofReproducció del document publicat a: http://dx.doi.org/10.1186/s13601-016-0137-4-
dc.relation.ispartofClinical and Translational Allergy, 2016, vol. 6, num. 47-
dc.relation.urihttp://dx.doi.org/10.1186/s13601-016-0137-4-
dc.rightscc by (c) Bousquet et al., 2016-
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/es/-
dc.sourceArticles publicats en revistes (ISGlobal)-
dc.subject.classificationAsma-
dc.subject.classificationFebre del fenc-
dc.subject.otherHay fever-
dc.subject.otherAsthma-
dc.titleARIA 2016: Care pathways implementing emerging technologies for predictive medicine in rhinitis and asthma across the life cycle-
dc.typeinfo:eu-repo/semantics/article-
dc.typeinfo:eu-repo/semantics/publishedVersion-
dc.date.updated2017-02-01T19:01:09Z-
dc.relation.projectIDinfo:eu-repo/grantAgreement/EC/FP7/261357/EU//MEDALL-
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess-
dc.identifier.pmid28050247-
Appears in Collections:Articles publicats en revistes (ISGlobal)
Articles publicats en revistes (IDIBAPS: Institut d'investigacions Biomèdiques August Pi i Sunyer)
Publicacions de projectes de recerca finançats per la UE

Files in This Item:
File Description SizeFormat 
bousquetj2016_2349.pdf1.4 MBAdobe PDFView/Open


This item is licensed under a Creative Commons License Creative Commons